Reporting at the 11th Annual T-Cell Lymphoma Forum in La Jolla, Calif., Miragen Therapeutics Inc. provided phase I data on cobomarsen in cutaneous T-cell lymphoma (CTCL) and adult T-cell leukemia/lymphoma (ATLL) along with a first look at prospects in diffuse large B-cell lymphoma (DLBCL).